Massively Undervalued 4.5% Dividend Yield In This Overlooked Growth Company

Income-focused investors have a compelling opportunity to add to their portfolios with this pick.

Investors in Takeda Pharmaceutical Company (TAK) have seen their shareholding experience significant price volatility over the past year:

While not as volatile as many other stocks in this market environment, TAK shares have been volatile on a 1-year beta basis over the past 12 months relative to the stock's historical beta.